|
Mechanism5α-reductase inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Xenna Corp.
0 Patents (Medical) associated with Xenna Corp.
100 Deals associated with Xenna Corp.
100 Translational Medicine associated with Xenna Corp.